First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations: The UNICORN Phase 2 Nonrandomized Clinical Trial

医学 奥西默替尼 内科学 临床终点 肺癌 非小细胞肺癌 肿瘤科 置信区间 临床试验 临床研究阶段 胃肠病学 外科 癌症 腺癌 A549电池 ROS1型
作者
Yusuke Okuma,Kaoru Kubota,Mototsugu Shimokawa,Kana Hashimoto,Yosuke Kawashima,Tomohiro Sakamoto,Hiroshi Wakui,Shuji Murakami,Kyoichi Okishio,Kenji Hayashihara,Yuichiro Ohe,Tokyo Cooperative Oncology Group (TCOG)
出处
期刊:JAMA Oncology [American Medical Association]
卷期号:10 (1): 43-43 被引量:114
标识
DOI:10.1001/jamaoncol.2023.5013
摘要

Importance: Non-small cell lung cancer (NSCLC) with uncommon EGFR mutations is a rare subgroup, composing 14% of all EGFR mutations. Objective: To determine the usefulness of osimertinib in previously untreated patients with metastatic NSCLC harboring uncommon EGFR mutations, excluding exon 20 insertion mutations. Design, Setting, and Participants: This multicenter, open-label, single-group, phase 2 nonrandomized clinical trial enrolled patients from April 10, 2020, to May 31, 2022, with a follow-up of 6 months from the date the last patient was enrolled. The study enrolled 42 patients with uncommon EGFR mutations, of whom 40 were eligible. Intervention: Osimertinib, 80 mg once daily, was administered orally to patients. Main Outcomes and Measures: The primary end point was the overall response rate (ORR). The secondary end points were disease control rate (DCR), progression-free survival (PFS), time to treatment failure (TTF), overall survival (OS), duration of response (DoR), and safety of osimertinib. Patients were included in the study on an intention-to-treat basis. Results: Of the 40 eligible patients, 22 were men (55.0%) and the median age was 72 years (range, 39.0-88.0 years). The most common mutations were G719X (20 [50.0%]), S768I (10 [25.0%]), and L861Q (8 [20.0%]). The ORR was 55.0% (90% CI, 40.9%-68.5%) and the DCR was 90.0% (95% CI, 76.3%-97.2%). The median PFS was 9.4 months (95% CI, 3.7-15.2 months) after a median follow-up of 12.7 months (range, 2.7-30.7 months). The median TTF was 9.5 months (95% CI, 5.6-30.3 months), median OS was not reached (NR; 95% CI, 19.3 months to NR), and median DoR was 22.7 months (95% CI, 9.5 months to NR). The ORR for patients with solitary or compound uncommon EGFR mutations was 45.5% (90% CI, 26.9%-65.3%) and 66.7% (90% CI, 43.7%-83.7%), respectively. Median PFS for patients with solitary or compound uncommon EGFR mutations was 5.4 months (95% CI, 3.6-22.7 months) and 9.8 months (95% CI, 5.1 months to NR), respectively. Median OS for patients with solitary or compound uncommon EGFR mutations was 23.0 months (95% CI, 12.3 months to NR) and NR, respectively. Median DoR for patients with solitary or compound uncommon EGFR mutations was 22.7 months (95% CI, 3.6-22.7 months) or NR (95% CI, 5.7 months to NR), respectively. Grade 3 or 4 adverse events were reported by 11 patients (27.5%), and 5 patients (12.5%) developed interstitial lung disease. All adverse events were manageable, and there were no treatment-related deaths. Conclusions and Relevance: Osimertinib showed clinical activity with manageable toxic effects among previously untreated patients with metastatic NSCLC harboring uncommon EGFR mutations other than exon 20 insertion mutations. The results support the use of osimertinib as a treatment option for this patient population. Trial Registration: Japan Registry of Clinical Trials Identifier: jRCTs071200002.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
天天向上的应助被长亭采纳,获得10
刚刚
真6完成签到,获得积分10
刚刚
刚刚
胡辣汤放糖完成签到,获得积分10
刚刚
科研通AI2S的应助被LEETHEO采纳,获得10
刚刚
journyjonas完成签到,获得积分10
刚刚
zewenjiang发布了新的文献求助10
刚刚
刚刚
一颗秋蝶完成签到,获得积分10
刚刚
Charlie发布了新的文献求助10
1秒前
1秒前
1秒前
纯情的浩然完成签到,获得积分10
1秒前
头发多多完成签到,获得积分10
1秒前
2秒前
2秒前
马照坤完成签到,获得积分10
2秒前
老帅比发布了新的文献求助10
2秒前
无敌啊豹完成签到,获得积分10
3秒前
min完成签到,获得积分10
3秒前
文献查找完成签到,获得积分10
3秒前
homelander完成签到,获得积分10
4秒前
橙尘尘完成签到,获得积分10
4秒前
4秒前
秋风的应助被穆礼稀采纳,获得20
4秒前
谨慎果汁发布了新的文献求助10
4秒前
独特乘云完成签到,获得积分10
4秒前
自立完成签到 ,获得积分10
5秒前
喝口可乐的应助被无昵称采纳,获得10
5秒前
微笑发布了新的文献求助10
5秒前
rr完成签到 ,获得积分10
5秒前
zyl完成签到,获得积分10
5秒前
快乐的哈密瓜完成签到,获得积分10
6秒前
6秒前
6秒前
爆米花的应助被LEETHEO采纳,获得10
6秒前
科研通AI2S的应助被sheeptime采纳,获得10
7秒前
7秒前
星辰大海的应助被mkl采纳,获得10
7秒前
july7292发布了新的文献求助10
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180488
求助须知:如何正确求助?哪些是违规求助? 9570485
关于积分的说明 21812623
捐赠科研通 7776592
什么是DOI,文献DOI怎么找? 3433286
关于科研通互助平台的介绍 2557522
邀请新用户注册赠送积分活动 2479162